Stockreport

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Cognition Therapeutics, Inc.  (CGTX) 
PDF – Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB – – Zervimesine- [Read more]